Article Text

Download PDFPDF
Drug development in IBD: from novel target identification to early clinical trials

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors SD, CF and JP participated in the conception, literature review and writing of the manuscript.

  • Funding This work has been in part supported by grants from Fondazione Humanitas per la Ricerca and FIRMAD to SD, and grant SAF 2012-33560, from Ministerio de Economía y Competitividad, Spain, to JP.

  • Competing interests SD has received consulting fees from and has served as a speaker, a consultant and an advisory board member for Schering-Plough, Abbott Laboratories, Merck & Co, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alphawasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo Nordisk, Salix, Cosmo Pharmaceuticals, Vifor and Johnson and Johnson. JP has received consulting fees from Abbvie, Boehringer Ingelheim, Galapagos, Genentech-Roche, Ferring, Janssen, MSD, Novo-Nordisk, Pfizer, Takeda and Tigenix.

  • Provenance and peer review Not commissioned; externally peer reviewed.